IMMP (IMMP) Stock Price & Analysis
IMMP (IMMP) rose 0.00% to USD 0.37 as of June 10, 2026 at 00:57 UTC, according to Nexqual real-time market data.
IMMP last closed at USD 0.37; the session ranged USD 0.35–0.37 on volume of 502,716 shares. Market capitalization is $54.37M, with a 52-week range of USD 0.29–3.53 (NGM). Source: Nexqual, June 10, 2026 at 00:57 UTC.
Key Statistics (as of June 10, 2026 at 00:57 UTC)
| Price | USD 0.37 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.37 |
| Open | USD 0.36 |
| Day Range | USD 0.35 – 0.37 |
| 52-Week Range | USD 0.29 – 3.53 |
| Volume | 502,716 shares |
| Market Cap | $54.37M |
| Exchange | NGM |
Technical Analysis (IMMP)
Nexqual's technical model rates IMMP "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.06 (oversold) |
| vs SMA50 | Below (USD 0.45) |
| MACD | -0.04 (negative) |
Analyst Ratings (IMMP)
Wall Street analysts rate IMMP "None", per Nexqual as of June 10, 2026 at 00:57 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (IMMP)
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financials & Fundamentals (IMMP)
| Total Revenue | $7.92M |
|---|---|
| Revenue Growth (YoY) | +91.50% |
| Gross Margin | +0.00% |
| Operating Margin | -763.71% |
| Profit Margin | +0.00% |
| ROE | -61.85% |
| Debt / Equity | 1.22 |
| Current Ratio | 2.97 |
| Total Cash | $99.13M |
| Total Debt | $1.21M |
| Free Cash Flow | $-35.68M |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financial Health Score (IMMP)
Nexqual rates IMMP's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:57 UTC.
| Growth | Strong — Revenue +32% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $99M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$36M, burning cash |
| Efficiency | Critical — ROE -62%, ROA -32.1% |
Ownership (IMMP)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +2.43% |
| Shares Outstanding | 147.37M |
| Float | 130.00M |
| Short % of Float | +3.03% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Leadership (IMMP)
IMMP is led by Marc Voigt (age 52), CEO, MD, CFO, Chief Business Officer & Executive Director, per Nexqual as of June 10, 2026 at 00:57 UTC.
| CEO, MD, CFO, Chief Business Officer & Executive Director | Marc Voigt (age 52) |
|---|---|
| COO, General Counsel & Joint Company Secretary | Deanne Miller LLB (age 48) |
| Chief Scientific Officer & Executive Director | Frederic Triebel (age 70) |
Major Backers & Investors (IMMP)
Notable institutional backers of IMMP include UBS Group AG, Meridian Wealth Management, LLC, Two Sigma Investments, LP, according to Nexqual as of June 10, 2026 at 00:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.51% |
| Meridian Wealth Management, LLC | 0.31% |
| Two Sigma Investments, LP | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.04% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc. | USD 22.23 | ▼ 0.09% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| SLS | SELLAS Life Sciences Group, Inc | USD 7.68 | ▼ 6.68% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:57 UTC. This page is informational and not investment advice.